bexotegrast
Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring
Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health
Roche to acquire 89bio in a deal worth up to US$3.5bn
With the agreement, Roche will gain a treatment for moderate to severe MASH
GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn
Steatotic liver disease affects approximately 5% of the global population
Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis
The drug has already been approved in the US to treat patients with non-cirrhotic MASH
Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis
The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease
Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC
Primary biliary cholangitis affects approximately 163,000 people in Europe
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
The company gained access to the drug through its $4.3bn acquisition of CymaBay
GSK’s linerixibat shows promise in phase 3 primary biliary cholangitis trial
An estimated 510,000 people will be diagnosed with the rare liver disease globally by 2030
Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis
The rare liver disease affects approximately 100,000 people in the US
Medscape Publication is Awarded Poster of Distinction at AASLD
Medscape Education is committed to disseminating the outcomes of the education programs through peer-reviewed publications and posters at leading medical conferences around the world. To this end, Medscape publishes more...
Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis
The disease affects approximately 25,000 people in the UK, the majority of whom are women
Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults
Approximately 25,000 people in the UK are affected by the rare liver disease